vs
ANI PHARMACEUTICALS INC（ANIP）与Gaming & Leisure Properties, Inc.（GLPI）财务数据对比。点击上方公司名可切换其他公司
Gaming & Leisure Properties, Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.7倍（$420.0M vs $247.1M），Gaming & Leisure Properties, Inc.净利率更高（57.0% vs 11.1%，领先45.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 6.3%），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 5.0%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
博彩与休闲地产公司（GLPI）是一家专注于赌场物业的房地产投资信托（REIT），总部位于宾夕法尼亚州怀奥米辛。公司于2013年11月从宾州国民娱乐分拆成立，目前持有62处赌场物业，全部对外出租给其他企业运营。
ANIP vs GLPI — 直观对比
营收规模更大
GLPI
是对方的1.7倍
$247.1M
营收增速更快
ANIP
高出23.4%
6.3%
净利率更高
GLPI
高出45.9%
11.1%
两年增速更快
ANIP
近两年复合增速
5.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $420.0M |
| 净利润 | $27.5M | $239.4M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 79.4% |
| 净利率 | 11.1% | 57.0% |
| 营收同比 | 29.6% | 6.3% |
| 净利润同比 | 367.5% | 40.5% |
| 每股收益（稀释后） | $1.14 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPGLPI
| Q1 26 | — | $420.0M | ||
| Q4 25 | $247.1M | $407.0M | ||
| Q3 25 | $227.8M | $397.6M | ||
| Q2 25 | $211.4M | $394.9M | ||
| Q1 25 | $197.1M | $395.2M | ||
| Q4 24 | $190.6M | $389.6M | ||
| Q3 24 | $148.3M | $385.3M | ||
| Q2 24 | $138.0M | $380.6M |
净利润ANIPGLPI
| Q1 26 | — | $239.4M | ||
| Q4 25 | $27.5M | $275.4M | ||
| Q3 25 | $26.6M | $241.2M | ||
| Q2 25 | $8.5M | $151.4M | ||
| Q1 25 | $15.7M | $165.2M | ||
| Q4 24 | $-10.3M | $223.6M | ||
| Q3 24 | $-24.2M | $184.7M | ||
| Q2 24 | $-2.3M | $208.3M |
营业利润率ANIPGLPI
| Q1 26 | — | 79.4% | ||
| Q4 25 | 14.1% | 89.3% | ||
| Q3 25 | 15.9% | 84.8% | ||
| Q2 25 | 6.6% | 61.3% | ||
| Q1 25 | 13.3% | 65.5% | ||
| Q4 24 | -2.3% | 79.1% | ||
| Q3 24 | -13.8% | 70.4% | ||
| Q2 24 | 3.7% | 77.1% |
净利率ANIPGLPI
| Q1 26 | — | 57.0% | ||
| Q4 25 | 11.1% | 67.6% | ||
| Q3 25 | 11.7% | 60.7% | ||
| Q2 25 | 4.0% | 38.4% | ||
| Q1 25 | 8.0% | 41.8% | ||
| Q4 24 | -5.4% | 57.4% | ||
| Q3 24 | -16.3% | 47.9% | ||
| Q2 24 | -1.7% | 54.7% |
每股收益（稀释后）ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | $1.14 | $0.96 | ||
| Q3 25 | $1.13 | $0.85 | ||
| Q2 25 | $0.36 | $0.54 | ||
| Q1 25 | $0.69 | $0.60 | ||
| Q4 24 | $-0.45 | $0.79 | ||
| Q3 24 | $-1.27 | $0.67 | ||
| Q2 24 | $-0.14 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $274.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $5.0B |
| 总资产 | $1.4B | $13.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPGLPI
| Q1 26 | — | $274.5M | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | $560.8M | ||
| Q3 24 | $145.0M | $560.8M | ||
| Q2 24 | $240.1M | $560.8M |
总债务ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | — | $6.9B | ||
| Q1 25 | — | $6.9B | ||
| Q4 24 | — | $7.7B | ||
| Q3 24 | — | $7.4B | ||
| Q2 24 | — | $6.6B |
股东权益ANIPGLPI
| Q1 26 | — | $5.0B | ||
| Q4 25 | $540.7M | $4.6B | ||
| Q3 25 | $505.8M | $4.6B | ||
| Q2 25 | $436.8M | $4.6B | ||
| Q1 25 | $418.6M | $4.2B | ||
| Q4 24 | $403.7M | $4.3B | ||
| Q3 24 | $405.9M | $4.3B | ||
| Q2 24 | $455.8M | $4.1B |
总资产ANIPGLPI
| Q1 26 | — | $13.8B | ||
| Q4 25 | $1.4B | $12.9B | ||
| Q3 25 | $1.4B | $12.8B | ||
| Q2 25 | $1.3B | $12.5B | ||
| Q1 25 | $1.3B | $12.1B | ||
| Q4 24 | $1.3B | $13.1B | ||
| Q3 24 | $1.3B | $12.7B | ||
| Q2 24 | $920.8M | $11.8B |
负债/权益比ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | — | 1.56× | ||
| Q3 25 | — | 1.57× | ||
| Q2 25 | — | 1.51× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | — | 1.74× | ||
| Q2 24 | — | 1.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | — |
| 自由现金流经营现金流 - 资本支出 | $29.1M | — |
| 自由现金流率自由现金流/营收 | 11.8% | — |
| 资本支出强度资本支出/营收 | 0.5% | — |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $171.4M | — |
8季度趋势，按日历期对齐
经营现金流ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $1.1B | ||
| Q3 25 | $44.1M | $240.3M | ||
| Q2 25 | $75.8M | $293.4M | ||
| Q1 25 | $35.0M | $252.5M | ||
| Q4 24 | $15.9M | $1.1B | ||
| Q3 24 | $12.5M | $270.4M | ||
| Q2 24 | $17.4M | $252.1M |
自由现金流ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $183.0M | ||
| Q2 25 | $71.8M | $272.3M | ||
| Q1 25 | $32.5M | $239.6M | ||
| Q4 24 | $13.5M | $1.1B | ||
| Q3 24 | $7.7M | $261.5M | ||
| Q2 24 | $13.0M | $245.0M |
自由现金流率ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | 46.0% | ||
| Q2 25 | 34.0% | 69.0% | ||
| Q1 25 | 16.5% | 60.6% | ||
| Q4 24 | 7.1% | 275.3% | ||
| Q3 24 | 5.2% | 67.9% | ||
| Q2 24 | 9.4% | 64.4% |
资本支出强度ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 14.4% | ||
| Q2 25 | 1.9% | 5.3% | ||
| Q1 25 | 1.3% | 3.3% | ||
| Q4 24 | 1.3% | 0.0% | ||
| Q3 24 | 3.2% | 2.3% | ||
| Q2 24 | 3.2% | 1.9% |
现金转化率ANIPGLPI
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 4.10× | ||
| Q3 25 | 1.66× | 1.00× | ||
| Q2 25 | 8.87× | 1.94× | ||
| Q1 25 | 2.23× | 1.53× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.46× | ||
| Q2 24 | — | 1.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GLPI
暂无分部数据
